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Abstract
Background: Hospital acquired pneumonia (HAP) is divided in two distinct groups, ventilator-associated
pneumonia (VAP) and non-ventilator-associated HAP (nvHAP). Although nvHAP occurs more frequently than VAP
and results in similar mortality and costs, prevention guidelines and prevention focus almost exclusively on VAP.
Scientific evidence about nvHAP prevention and its implementation is scarce. Therefore, we designed a mixed-
methods hybrid type 2 effectiveness-implementation study to investigate both the effectiveness and
implementation of a newly developed nvHAP prevention bundle.
Methods: This single-centre project at the 950-bed University Hospital Zurich (UHZ) will engage the wards of nine
departments with substantial nvHAP rates. The nvHAP bundle consists of five primary prevention measures: 1) oral
care, 2) prevention of dysphagia-related aspiration, 3) mobilization, 4) stopping unnecessary proton pump inhibitors,
and, 5) respiratory therapy. Implementation includes the engagement of department-level implementation teams,
who sustain the ‘core’ intervention components of education, training, and environmental restructuring and tailor
the implementation strategy to local needs. Both effectiveness and implementation outcomes will be assessed
using mixed-methods. As a primary outcome, nvHAP incidence rates will be analysed by Poisson regression models
to compare incidence rates before, during, and after the implementation phases (on the hospital and department
level). Additionally, the association between process indicators and nvHAP incidence rates will be analysed using
longitudinal Poisson regression models. A longitudinal, qualitative study and formative evaluation based on
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interviews, focus groups, and observations identifies supporting or hindering factors for implementation success in
participating departments dynamically over time. This accumulating implementation experience will be constantly
fed back to the implementation teams and thus, represents an active implementation element.
Discussion: This comprehensive hybrid mixed-methods study is designed to both, measure the effectiveness of a
new nvHAP prevention bundle and multifaceted implementation strategy, while also providing insights into how
and why it worked or failed. The results of this study may contribute substantially to advancing knowledge and
patient safety in the area of a rediscovered healthcare-associated infection - nvHAP.
Trial registration: ClinicalTrials.gov: NCT03361085. Registered December 2017.
Keywords: Hospital-acquired pneumonia, Aspiration pneumonia, Infection prevention, Care bundle, Mixed-methods
study, Implementation science, Qualitative research
Background
Hospital acquired pneumonia (HAP) is defined as pneumo-
nia with first symptoms ≥48 h after admission. It is divided
into two distinct groups, ventilator-associated pneumonia
(VAP) and non-ventilator-associated hospital acquired
pneumonia (nvHAP). Together, HAP and lower respiratory
tract infections were shown to be the most common
healthcare-associated infections (HAI) in both the Euro-
pean point prevalence study of 2011/2012 and the multi-
state U.S. point prevalence study in 2011 [1, 2]. In these
studies, more than half of HAP - 67 and 61% - were nvHAP
[1, 2]. Further, nvHAP leads to substantial morbidity and
was shown to have comparable mortality and similar costs
as VAP [3]. However, current research and prevention ef-
forts still focus almost exclusively on VAP.
Scientific evidence about prevention of nvHAP is scarce
and of limited quality [4]. There are no formal recommen-
dations or evidence-based guidelines for nvHAP, and the
existing HAP prevention guidelines focus almost exclu-
sively on VAP [5–7]. In a narrative review, Passaro et al.
highlighted that oral care is the most studied measure and
was commonly associated with a decreased HAP rate, al-
though a broad range of interventions are proposed [4].
Evidence is lacking for other measures such as dysphagia
programs, early mobilization, and head of bed elevation
[4]. The estimated proportion of preventable HAI in gen-
eral ranges from 10 to 70% [8, 9], and the preventable pro-
portion of VAP specifically was reported to be 52–55%
[10, 11]. In a systematic literature review and meta-
analysis about the proportion of HAI that could be pre-
vented with multifaceted interventions only two of 132 in-
cluded studies dealt with the prevention of nvHAP [9].
Hiramatsu et al. found that an outpatient bundle of
nvHAP prevention measures, comprising three proce-
dures of breathing exercises, two procedures of oral care,
a procedure of nutritional control and smoking cessation
prior to planned surgery, was effective to prevent postop-
erative pneumonia among patients with oesophageal can-
cer [12]. Kazaure et al. found that use of an incentive
spirometer, oral hygiene with chlorhexidine, ambulation
with good pain control and head-of-bed elevation to at
least 30° and sitting up for all meals, accompanied by ini-
tial and ongoing education, progress reports, prevention
measure documentation and order sets lead to a 43.6% de-
crease of postoperative pneumonia in non-cardiac surgical
patients [13]. To our knowledge, there are no studies
evaluating the effectiveness of an nvHAP prevention bun-
dle on a broad patient population.
Implementation science is the scientific study of
methods to promote uptake of evidence-based best prac-
tices into routine healthcare practice [14]. Although qual-
ity improvement studies often report on the effectiveness
of studied interventions to improve both, process indica-
tors and patient outcomes, little is usually reported about
the context of the intervention and what factors played a
role in the successful implementation of practice mea-
sures. Further, the implementation strategies used in such
studies are often described in poor detail and lack theoret-
ical justification, therefore hindering the development of
an evidence base for their effectiveness [15–17]. A detailed
understanding of not only what works, but also how and
why it works, is helpful to ensure that evidence-based
practices of proven effectiveness can be successfully repli-
cated and implemented in other settings. To simultan-
eously evaluate our multifaceted implementation strategy
while also testing the effectiveness of the clinical nvHAP
prevention bundle, we undertake a type 2 hybrid
effectiveness-implementation study [18, 19].
This comprehensive type 2 hybrid effectiveness-
implementation study aims to assess the effectiveness
and success factors of both, a new prevention bundle
against nvHAP and a specifically designed department-
based multifaceted implementation strategy in a medical




With this mixed-methods study, we aim to investigate
the impact of the implementation of a newly designed
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nvHAP prevention bundle on the nvHAP incidence rate
among inpatients in our tertiary care hospital. We will
quantify the adherence to the individual bundle elements
and qualitatively identify the factors that influence suc-
cessful implementation.
Objectives
1. To determine the nvHAP bundle effectiveness on
the nvHAP incidence rate
2. To determine adherence to the nvHAP bundle and
each of the bundle elements
3. To relate adherence to nvHAP bundle elements
with nvHAP incidence rate
4. To qualitatively monitor changes and identify
trends in implementation outcomes throughout the
study periods
5. To identify which factors in the implementation
setting are associated with the actual degree of local
implementation of the nvHAP bundle
Study setting
The study is conducted at the University Hospital Zurich
(UHZ), Switzerland, a 950-bed tertiary-care teaching
hospital covering all medical specialties except paediat-
rics and orthopaedics.
Study population
All patients hospitalized in nine predefined medical and
surgical departments and their corresponding wards will
be included in this study. The nine departments were
chosen based on the following criteria; 1) nvHAP rate
above the 50th percentile according to UHZ nvHAP data
from the year 2017; 2) high absolute number of patients
with nvHAP according to UHZ nvHAP data from the
year 2017; 3) organizational structure, e.g. departments
sharing same nursing or medical personnel; 4) represent-
ing both medical and surgical specialties.
Intervention
Clinical intervention: the nvHAP bundle
The University Hospital Zurich nvHAP bundle was de-
signed by an interprofessional and interdisciplinary
group of experts. Elements were chosen based on the
evidence, although scarce, of their effectiveness and
based on their anticipated feasibility and implementabil-
ity. The bundle consists of five prevention measures (de-
tails see Additional file 1 nvHAP Bundle).
1. Oral care, i.e. mechanical oral care with or without
pharmacological products, once daily in all patients, and
three times daily in patients with swallowing difficulties.
2. Prevention of dysphagia-related aspiration, i.e.
applying a ‘modified swallowing assessment’ (MSA)
adapted from the ‘Standardized Swallowing Assessment’
by Perry et al. [20] (Additional file 2 ‘MSA Perry’) in a
defined risk population, followed by further evaluation
and treatment of dysphagia residing with the responsible
physicians.
3. Mobilization, i.e. mobilization at least once at the
day of surgery and at least twice daily in all other pa-
tients without contraindications.
4. Stopping unnecessary PPI and antacids, accord-
ing to a list of indications in in-hospital guidelines.
5. Respiratory therapy, i.e. referral to respiratory
therapists advised for a defined patient population, with
a final decision at the discretion of the responsible
physician.
All patients will be assessed regarding whether an ac-
tive intervention of healthcare providers is indicated for
each of the prevention measures at the following time
points: after admission, after clinical deterioration, and
after major surgery during. If yes, the prevention meas-
ure is executed according to the above description. The
execution of the bundle element will be documented in
the electronic medical record (EMR).
Implementation strategy and formative evaluation
Our multifaceted implementation strategy is designed to
increase ownership and local adoption in each depart-
ment by engaging local implementation teams, who es-
tablish department-specific actions tailored to local
needs. This strategy is also intended to facilitate adapt-
ability, i.e. the degree to which the intervention can be
adapted to meet local needs [21, 22]. Based on an initial
behavioural analysis informed by sensitizing frameworks
(see below, “Implementation Frameworks”) [21, 23, 24],
we identified the following as promising intervention
functions to increase adherence to the nvHAP bundle:
increasing knowledge and understanding about the
nvHAP bundle elements through education; imparting
skills through technical training; and changing the phys-
ical context to increase awareness and support perform-
ance of nvHAP measures through environmental
restructuring. Whereas these intervention functions to
increase adherence to the nvHAP bundle elements make
up the foreseeable core intervention components, each
department is encouraged to adapt the delivery of these
components and to employ additional promotional com-
ponents according to local context, making up the
‘adaptable periphery’ of the intervention [21].
Local implementation teams, composed of one nurse,
one physician and one physiotherapist, will be estab-
lished in each department. During recurrent “action
plan” meetings, the local implementation team from
each department, with support from the nvHAP study
team, will be responsible for assessing the current imple-
mentation status with respect to each bundle element
and establishing an “action plan” with a list of planned
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actions aimed to increase adherence to bundle elements
according to local needs. Local implementation teams
will be responsible for implementing the nvHAP bundle
in their respective departments. Established “action
plans” will be revisited to assess progress and refine ne-
cessary actions, as described below.
The nvHAP study team, based in the infection preven-
tion department, will form a central coordinating team to
provide local teams with support, example training mate-
rials, and feedback on process and outcome data. Add-
itionally, we will employ a formative approach, during
which we aim to continuously identify influences on im-
plementation efforts (e.g. barriers and facilitators) and feed
these insights back to local implementation teams to
optimize the potential for implementation success [25].
This formative evaluation will occur in stages throughout
the project, as described by Stetler and colleagues [25] and
presented in Table 1. The formative evaluation will rely
primarily on “action plan” meetings as an opportunity to
feed information back to local implementation teams re-
garding identified barriers and facilitators to implementa-
tion and to refine implementation action plans
accordingly.
Study design
This mixed methods study collects and analyses quanti-
tative and qualitative data collected during the three
study periods (baseline, implementation, and interven-
tion period). The conceptual model of the study is
depicted in Fig. 1.
Outcomes
Effectiveness outcomes The primary outcome is
nvHAP incidence rate, defined as the number of patients
suffering from nvHAP per 1000 patient days per month.
Secondary outcomes are in-hospital mortality rate;
length of stay; and adherence to individual bundle ele-
ments and the nvHAP bundle as a whole.
Implementation outcomes We will use a qualitative
definition of implementation success composed of the
following four implementation outcomes [26]: 1) accept-
ability, how satisfied are study participants with the
intervention; 2) appropriateness, what is the perceived fit
of the intervention and to what extent did participants
succeed in adapting the intervention to meet the needs
of their local context; 3) implementation fidelity, how
closely did participants succeed in implementing the
core bundle components as described in the study
protocol; and 4) sustainability, to what extent did the
intervention become institutionalised and anchored
within ongoing operations. Implementation outcomes
will primarily be assessed qualitatively through semi-
structured interviews at multiple time points throughout
the project, both, to assess implementation progress and
to inform our formative evaluation (Table 1). Implemen-
tation fidelity will further be assessed through observa-
tion and artefact analysis by comparing planned and
actual implementation activities. Quantitative data on
adherence to the five bundle measures, as described
below, will also be considered in assessing implementa-
tion fidelity. Sustainability will be particularly assessed
by identifying examples of how the intervention has
been integrated into local processes and structures such
that it is likely to continue as a part of stable operations
[26]. In assessing implementation outcomes at multiple
time points, we aim to identify what has been described
by Proctor and colleagues as “leading” and “lagging” in-
dicators of implementation success [26] – where leading
indicators are those that reflect the outcome of a change
Table 1 Formative Evaluation Stages
Stage Aims Concretization in current study
1. Developmental evaluation,
“diagnostic analysis”
Assess levels of current practices and
their determinants
Prospectively identify potential barriers
and facilitators to implementation
During the baseline period “Action Plan” interview with
local implementation teams, the current state of practice
for each nvHAP bundle measure will be assessed and
determinants of current behaviour discussed.
An “Action Plan” of promotional activities will be established,
taking into account potential barriers and facilitators.
2. Implementation-focused
evaluation
Assess discrepancies between established
implementation plan and its operationalization
Continually identify barriers and facilitators to
implementation
Refine implementation plan
During the “Action Plan” interview with local implementation
teams following the implementation period, the previously
established “Action Plan” will be revisited and actual vs.
planned interventions assessed. Refinements to the action
plan will be made as needed taking into account newly
identified barriers and facilitators.
3. Progress-focused evaluation Monitor and inform stakeholders about progress
towards goals
During the Intervention period, feedback about nvHAP
outcomes and process indicators will be fed back to local
implementation teams.
4. Interpretive evaluation Triangulate qualitative and quantitative data to
enhance understanding of implementation
results
Upon project completion, qualitative findings will be used
to illuminate quantitative results and inform guidance about
how the nvHAP bundle can best be implemented in further
settings.
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in practice early on or even predict it, and lagging indi-
cators reflect the delay between a change in practice and
the observable outcomes.
Study periods on department and hospital level
Baseline period will start at the same time for all depart-
ments and will be of different length (minimum 12
months) as implementation of nvHAP prevention mea-
sures will occur at the department level and the start of
implementation activities is chosen by every department,
primarily relying on availability of resources.
We define three study periods on the department level,
1) department baseline period, before implementation of
nvHAP bundle in the specific department; 2) department
implementation period, a two month time frame starting
with the beginning of implementation activities in the
respective department; 3) department intervention
period following the department implementation period.
On the hospital level the three periods are defined as
follows: 1) hospital baseline period, before starting im-
plementation in the first department; 2) hospital imple-
mentation period, from the beginning of the
implementation period of the first department until end
of implementation period of the last included depart-
ment; 3) hospital intervention period following the hos-
pital implementation period. Figure 2 depicts an
anticipated study timetable.
Quantitative and qualitative data collection will con-
tinue throughout the project and follows the study pe-
riods on the department level (Fig. 3).
Fig. 1 Conceptual model
Legend: nvHAP = non-ventilator-associated healthcare-acquired pneumonia. This figure portrays the conceptual model of the nvHAP
implementation process, in which the entire implementation process is moderated by the context in which the process is set. The contextual
influencers of implementation include the larger organizational setting (i.e. the hospital and wider national context), the inner setting (i.e. the
departments in which the bundle is being implemented), as well as the characteristics of individuals directly and indirectly involved in the
implementation process. The contextual influencers moderate the effectiveness of specific intervention components used to implement the
nvHAP bundle elements in participating departments, resulting in varying levels of implementation success, as reflected by levels of adherence to
bundle components, and ultimately by the resulting outcome measures
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The first department (pilot department) is used to test
quantitative and qualitative data collection tools and the
feasibility of the implementation strategy. Insights from
this pilot department will help to improve the imple-
mentation strategy and study tools prior to the inclusion
of further departments.
Implementation frameworks
Our study is theoretically informed by the Consolidated
Framework for Implementation Research (CFIR) [21] and
the Theoretical Domains Framework (TDF) [23]. Both the
CFIR and the TDF integrate findings from theoretical lit-
erature into synthesized frameworks consisting of con-
structs that may mediate behaviour change [21, 23].
Whereas the TDF domains represent a set of constructs
related to individual behaviour change, the CFIR domains
include constructs relating to broader organizational be-
haviour change. For the current inquiry, we find the use of
both frameworks useful to capture influencers of behav-
iour at the individual level, as well as the department, the
overall hospital, and the wider environmental context.
The CFIR and the TDF will inform the intervention im-
plementation strategy, as previously described, and guide
the qualitative data collection (semi-structured interview
guides) and analyses (use of TDF as deductive coding
framework). In particular, use of these sensitising frame-
works throughout our study will facilitate the timely iden-
tification of barriers and facilitators and will also provide
insights as to which additional intervention components




In the study hospital, all patient data are charted elec-
tronically via an EMR system. Selected data are stored in
a clinical data warehouse.
Quantitative data collection
NvHAP surveillance We apply the European Centre for
Disease Prevention and Control (ECDC) definition cri-
teria for pneumonia that are used in the ECDC point
prevalence studies [27] (Additional file 3 ‘ECDC nvHAP
definition’). In brief, the pneumonia definition comprises
radiologic criteria, systemic symptoms (fever > 38 °,
leukopenia or leukocytosis) and pulmonary symptoms
(e.g. cough, sputum production). Pneumonia is defined
as hospital-acquired, if symptoms start ≥48 h after ad-
mission. If an invasive respiratory device was present in
the 48 h preceding symptom onset, the pneumonia is
considered a ventilator-associated pneumonia and thus
not subject of this study. A validated semi-automated
surveillance system for nvHAP is used [28]. Place of
nvHAP acquisition is defined as department, ward and
room to which the patient was affiliated 48 h before first
symptoms of nvHAP, unless shorter incubation period
is evident from patient history.
Process indicators Process indicators portraying adher-
ence to the nvHAP bundle elements will be monitored in
two ways. First, for all five prevention measures, at least
one surrogate parameter for adherence is continuously ex-
tracted from the EMR of the total patient population
(continuous process indicators; see Additional file 4
‘Process indicators’). This parameter, e.g. tooth brushing
provided by nurses, will be expressed per department, and
month, and per hospital days. Second, we will monitor
process indicators on a sample basis with individual as-
sessment of a subset of 50 patients (denominator) at four
different time points per department (intermittent process
indicators; see Additional file 4 ‘Process indicators’). The
latter allows a more detailed description of adherence, in-
cluding non-documented prevention measures (e.g. oral
care executed by patient) and takes into consideration the
individual need of patients for the specific prevention
measure (e.g. respiratory therapy is indicated only in a












































































































































































































































Fig. 2 Study time table for department and hospital level (example of anticipated inclusion time points)
Legend: Department and hospital baseline period (i.e. before implementation, light grey), followed by implementation period (i.e. during
implementation, shaded), and intervention period (i.e. after implementation, dark grey)
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indicators the ‘nvHAP adherence score’ will assess patient
based adherence per department and time point. The
score is based on samples of 50 patients, the ‘nvHAP ad-
herence indicator’ takes the value 1 in the case the specific
prevention measure was completed in the specific patient,
0 if that was not the case, and “empty” in the case of miss-
ing values. The ‘nvHAP adherence score’ is calculated by
summing up the five proportions of patients with com-
pleted specific prevention measures (i.e. ‘nvHAP adher-
ence indicator’=1) dividing it by factor five
(Additional file 5 ‘nvHAP adherence score’).
Qualitative data collection
Longitudinal qualitative data will be collected through-
out the project as portrayed in Fig. 3, including action
plan interviews with local implementation teams, drop-
in interviews with frontline staff, and focus group inter-
views, as described in Table 2. The researchers involved
in qualitative data collection and analysis, who are also
part of the implementation team, will seek to demon-
strate empathic neutrality [29], for example by prefacing
interviews with the fact that we are interested in learning
about implementation experiences and that there are no
right or wrong answers. In doing so, we hope to limit
desirability bias in the information shared. Having three
data collection activities will also allow for rigorous tri-
angulation of findings among data sources and will all
inform the ongoing formative evaluation (see Table 1).
For drop-in and focus groups interviews, participants
will be purposefully sampled to include a representative
mix of professions (nurses, physicians, and physiothera-
pists) from wards within the participating departments
Given inconsistencies in definition and application of
‘saturation’ as a measure of sufficient sampling,
‘information power’ has been proposed as a concept to
guide adequate sample size [30]. By having a clearly de-
fined qualitative study aim, an information-rich sample
of interview participants, guiding theoretical frameworks
to inform structured data collection by skilled inter-
viewers expert in the study topic, our study design and




Analyses of nvHAP bundle effectiveness To evaluate
the effectiveness of the intervention bundle, two distinct
analyses are performed. First, a change point model will
be combined with piecewise constant rates with additional
sine-cosine waves to account for seasonality. Poisson re-
gression (with log link function) is used to analyse the
monthly overall nvHAP incidence rate over all depart-
ments, using the monthly sum of the nvHAP cases over
all departments as “count” and the monthly sum of the
number of patient days (in thousands) over all depart-
ments as offset. Study period on the hospital level (hos-
pital baseline, implementation, intervention period) will be
used as explanatory factor (see Additional file 6 ‘Statistical
analysis’ for detailed statistical model). We may use a
quasi-poisson model in case of overdispersion.
Second, a longitudinal Poisson regression will be used.
The monthly number of nvHAP cases in each depart-
ment will be modelled by a generalized estimating equa-
tion (GEE) with departments as clusters. This allows to
account for the non-independence of consecutive
nvHAP counts within departments, to model the tem-
poral correlation structure (e.g. first order autoregres-
sive) and to account for over-dispersion, if necessary.
Fig. 3 Study periods and data collection in a single exemplary department
Legend: The baseline period of 12 months or longer is followed by an implementation period defined to be 2months long, and an intervention
period of again 12 months or longer. The figure depicts the data collection time points, with squares indicating quantitative data collection and
circles indicating qualitative data collection time points
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We will assume a Poisson error distribution for the
nvHAP counts and use the log link function. As above,
we may use a quasi-Poisson model in case of overdisper-
sion. We will use a time-dependent, department-specific
binary indicator variable for department-level implemen-
tation of the intervention bundle (possibly with an inter-
mediate level for the implementation phase) as
explanatory variable. Further, we will adjust for seasonal-
ity of nvHAP incidences by inclusion of sine/cosine
waves.
Because the baseline period includes nvHAP rates
from 2017 which served (inter alia) as basis for the
choice of the nine departments, we will perform sensitiv-
ity analyses excluding data from 2017 for all analyses de-
scribed above to assess a potential “regression to the
mean” effect.
Analyses of process indicators To portray adherence
to the single prevention measures and the nvHAP bun-
dle as a whole a descriptive analysis will be performed,
summarizing continuous and intermittent process indi-
cators and the ‘nvHAP overall adherence score’ by
department-level periods. Further, we will evaluate
whether the process indicators are associated with the
nvHAP incidence rate. We will use GEEs with Poisson
error and departments as clusters (as described above)
to model the monthly nvHAP rates as dependent on ei-
ther single continuous process indicators or on all con-
tinuous process indicators combined.
To model monthly nvHAP as dependent on intermit-
tent process indicators (either single process indicators,
all process indicators combined, or the nvHAP overall
adherence score), we will use GEEs with Poisson error
and departments as clusters (as described above). Be-
cause the intermittently collected process indicators are
collected only at four time points, we will use linear
interpolation to derive monthly values for these process
indicators.
Qualitative analysis
Longitudinal qualitative data from drop-in, action-plan
and focus group interviews will be included in a cross-
case analysis, where each participating department rep-
resents a case. In a first step, all interview transcripts
and notes will be coded deductively using the Theoret-
ical Domains Framework (TDF) as a coding scheme as
well as additional codes to capture our pre-defined im-
plementation outcomes [23]. Inductive thematic analysis
will then be conducted to identify themes relevant to the
implementation within TDF domains. Analyses will
begin with at the case level to understand the local influ-
encers of implementation at the department level, allow-
ing us, for example, to assess how implementation
outcomes shift over time in relation to the undertaken
interventions and in light of local barriers and facilita-
tors. Then, cross-case matrices will be used to explore
any trends across departments [31]. This qualitative ana-
lysis will allow us to make a qualitative assessment about
which local factors and interventions contributed to im-
plementation success. Our in-depth findings will also
help to ultimately shine light on quantitative study re-
sults. The researchers involved in qualitative analysis will
engage in an ongoing process of reflexivity [29], consid-
ering the role of our own preconceptions and close rela-
tion to the implementation process, while also aiming to
provide an authentic account of the implementation
process.
Discussion
With this mixed-methods study we will close critical
knowledge gaps about the prevention of nvHAP, a
neglected but common HAI. To date, literature about
prevention measures against nvHAP is scarce [4], and
our study will provide further knowledge by assessing
the effectiveness of a five element prevention bundle
against nvHAP on lowering nvHAP incidence rates. To
our knowledge, it is the first study testing an inpatient
bundle of nvHAP prevention measures on a broad








Semi-structured interviews of approximately one hour
to assess the current implementation status of each
nvHAP bundle element throughout the study periods,
as well as identify potential or actual barriers and
facilitators to implementation, and plan a list of actions
to be taken locally.
Interviews will be audio-recorded and transcribed
where acceptable and structured notes will be taken
systematically. These and the written action plan
documents established after each interview will
be included in qualitative analysis.
Drop-in interviews Frontline
clinicians
Short, semi-structured, drop-in interviews of 10–15 min
to learn from frontline staff about their experience with
the nvHAP implementation and identify local barriers
and enablers to implementation.
Detailed, structured notes will be taken during and
after each drop-in interview and/or the interview will
be audio-recorded and transcribed verbatim to be





Semi-structured focus group interviews of approximately
1 h to assess implementation outcomes among frontline
staff.
Focus groups will be audio-recorded and transcribed
verbatim for inclusion in qualitative analysis.
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patient population. Moreover, as effective implementa-
tion is as important as choosing the right bundle ele-
ments [14, 32], we place focus on a theoretically-
informed implementation strategy.
The quantitative part of the study aims to not only
measure the primary outcome parameter nvHAP inci-
dence rate over time, but to also measure process indica-
tors. This will help us to better understand if the
implementation process was successful and to evaluate
direct association between prevention measures and
nvHAP incidence rate. As the nvHAP bundle cannot be
effective if it is not well implemented, it is important to
also measure implementation outcomes (e.g. acceptabil-
ity, appropriateness, fidelity, and sustainability) as neces-
sary preconditions for achieving the desired changes in
clinical outcomes.
A major strength of this study is the mixed-methods ap-
proach, including an extensive formative qualitative study
to provide insights about how and why departments suc-
ceeded, or faced challenges, in implementing the nvHAP
bundle. With some notable exceptions [33–36], many
qualitative implementation evaluations are limited to in-
quiries conducted at a single point in time. Such inquiries
are prone to participant recall biases and may be insuffi-
cient to telling the whole implementation story [26]. Our
longitudinal qualitative study aims to provide critical con-
textual insights to guide others hoping to implement the
nvHAP bundle. Additionally, the participatory approach
of our formative evaluation is intended to increase project
commitment among stakeholders, particularly local imple-
mentation teams.
The limitations of our study are the following: First,
our study does not include a control group. We
abstained from conducting a randomized controlled trial
due to anticipated high contamination between depart-
ments/wards within the same hospital. Second, the dur-
ation of the implementation period is determined to be
2 months not accounting for possibly longer duration
due to the formative approach of the implementation
strategy. We aim to address this point by analysing the
results both on the hospital and department level. Third,
by continuously collecting process indicators from EMR,
we cannot preclude reporting bias (e.g. increased docu-
mentation of oral care). We address this issue by add-
itionally measuring process indicators on an individual
basis. Further, although we take efforts to demonstrate
empathic neutrality during our qualitative data collec-
tion, we cannot entirely preclude the possibility that
qualitative researchers may be perceived as being partial,
leading to potential desirability bias in the qualitative
data. Finally, we acknowledge that our formative process
evaluation does in itself lead to changes in implementa-
tion plans and that these changes must be documented
with great care to keep track of the exact
implementation activities. Rather than purely a limita-
tion, we view this as a strength of our study, and we an-
ticipate that it should also be integrated into
recommendations for those wishing to replicate results
of our future nvHAP study.
In conclusion, with this innovative mixed-methods
study design, we will assess the effectiveness of the
nvHAP bundle, but also measure process indicators of
the nvHAP bundle and contextual factors influencing
implementation uptake. We will be able to triangulate
our findings, i.e. correlate nvHAP rates with adherence
data of the prevention bundle and again with qualitative
measures of implementation success. Further, our
mixed-method approach will be of great value to under-
standing the complex contextual interactions that influ-
ence implementation success, which are necessary to
inform implementation guidance for other institutions
planning to implement the nvHAP bundle.
Addendum: Due to the COVID-19 pandemic, the
study data collection had to be terminated earlier than
planned (i.e. end of February 2020). Additional file 7
informs about the details of early study termination.
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